There is increasing evidence suggesting potential new treatments, such as the ERβ agonist LY500307 that suppresses lung cancer metastasis by activating antitumor neutrophils (58), or the utilization of newly designed SERDs that interact with ER-positive immune cells to improve the response to immune checkpoint inhibitors in breast cancer (24). Here, ESR1 is linked to breast cancer.